Pelizzon David R 4
Research Summary
AI-generated summary
Orthopediatrics Director David Pelizzon Receives Award of 11,436 Shares
What Happened
- David R. Pelizzon, a director of Orthopediatrics Corp. (KIDS), received a grant/award of 11,436 shares on June 9, 2026. The shares were reported at a $0.00 acquisition price, so the immediate cash value shown on the Form 4 is $0. This filing reports an equity award (code A), not a purchase or sale.
Key Details
- Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (filed the next day).
- Shares granted: 11,436; price per share reported: $0.00; reported acquisition value: $0.
- Shares owned after transaction: not specified in the information provided in this summary (not reported here).
- Footnote F1: the filing notes restricted stock awards totaling 17,959 shares are included in the beneficial ownership figures on the form.
- Footnote F2: certain shares are held by Squadron Capital LLC; Pelizzon, as President and a Managing Committee member of Squadron, may be deemed to have beneficial ownership of those shares but expressly disclaims beneficial ownership except to the extent of any pecuniary interest.
Context
- This was an equity award (restricted stock), which typically vests over time and is not an immediate sale—awards are compensation, not a market purchase signal. The $0 reported price indicates a grant rather than a cash purchase. The Squadron-related footnote reflects attribution rules for holdings tied to an entity Pelizzon helps manage; he disclaims direct beneficial ownership except for any personal economic interest.